ArticleBMC public health2025
Epidemiological features of hypertension in a high-altitude population in Tibet, China: a cross-sectional study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characteristics and influencing factors of self-management behaviors of hypertensive patients in areas with concentrated ethnic minorities on plateau: a latent profile analysis.BMC public health · 2026Article
- Study on the mechanism of Ershiwei Chenxiang Pills in the treatment of high altitude hypertension based on network pharmacology and molecular docking analysis.Die Naturwissenschaften · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a significant public health challenge in high-altitude areas of Tibet, China. This study aimed to investigate the current epidemiologic status of hypertension in Tibet and to provide insights for enhancing prevention and control strategies in this population.
methodsA cross-sectional study was conducted across seven cities in the Tibet autonomous Region. Using multi-stage stratified cluster sampling, 8,992 residents aged 35-75 were enrolled. Hypertension prevalence, awareness, treatment, control rates, and associated risk factors were analyzed. We conducted descriptive and logistic regression analyses in this study.
resultsThe crude and weighted hypertension prevalence rates were 46.5% and 46.7%, respectively. Stage 2 or higher hypertension accounted for 49.8% of cases. Among hypertensive individuals, 45.2% were aware of their diagnosis, 30.8% received treatment, and only 3.0% achieved blood pressure control. Risk factors included aging, urban residence, alcohol consumption, overweight, obesity, diabetes, and central obesity (all p < 0.05). Monotherapy was used by 94.2% of treated patients, predominantly calcium channel blockers (CCBs). Among CCBs, nifedipine was the most commonly used agent (38.2%), with women more likely to use CCBs and less likely to receive beta-blockers than men (p < 0.05).
conclusionsHypertension in Tibet is characterized by high prevalence, multifactorial risk, and critically low rates of awareness, treatment, and control. Strengthening primary healthcare infrastructure and targeted health promotion programs are urgently needed to address this burden in high-altitude populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.